Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer

Chellan Kumarasamy, Rama Jayaraj

Research output: Contribution to conferenceConference paper presented at Conference (not in Proceedings)Research

Abstract

Background: A large number of immunohistochemical biomarkers that function as prognostic markers in Head and Neck Cancer (HNC) have been discovered in the past 3 decades. Despite these advancements, there is currently no designated IHC marker that sees widespread clinical use as a standard prognostic marker in HNC. Furthermore, there are very few studies that comprehensively analyse the prognostic comparative utility of these immunohistochemical markers, with the previously published studies being primarily literature reviews. Therefore, this is aimed at investigate the prognostic significance of the various immunohistochemical biomarkers identified in HNC through systematic review and meta-analysis.

Methods: Clinical study data pertaining to the prognostic efficacy of IHC markers in HNC is obtained by a thorough search of bibliographic databases such as, MEDLINE, Scopus, PubMed, Web of Science, EMBASE and Science Direct, using a combination of ‘keywords’ to develop database ‘search strings’. Relevant studies are screened for and selected using strict, predefined inclusion and exclusion criteria, by two independent reviewers. HNC patient data is extracted from eligible studies using a pre-piloted data extraction form. Quantitative synthesis will be performed on patient survivaldata (with respect to the IHC markers) extracted from the selected studies as explicitly recordedstatistics or from the Kaplan-Meier (KM) Curves of the studies. A forest plot will be generated, todetermine pooled Hazard Ratios (HR) and 95% Confidence Interval (CI).

Discussion: There are a number of immunohistochemical biomarkers that have been discovered for estimating the prognosis of HNC patients’ clinical outcomes including. This systematic review will serve to compare and highlight IHC markers that show promising prognostic properties. Highlighting these prognostic specific IHC markers will have major clinical implications by allowing for betterestimation of disease recurrence and patient survival, by offering clinicians a method ofquantitatively analysing the value of prominent IHC markers used to assess prognosis in HNC.

Original languageEnglish
Publication statusPublished - 2018
EventAdelaide Immunology Retreat 2018 - McCracken Country Club, Victor Harbor, Australia
Duration: 10 Aug 201811 Aug 2018
Conference number: 14

Conference

ConferenceAdelaide Immunology Retreat 2018
Abbreviated titleAIR-14
CountryAustralia
CityVictor Harbor
Period10/08/1811/08/18

Fingerprint

Head and Neck Neoplasms
Biomarkers
PubMed
MEDLINE
Meta-Analysis
Databases
Confidence Intervals
Recurrence
Survival

Cite this

Kumarasamy, C., & Jayaraj, R. (2018). Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer. Paper presented at Adelaide Immunology Retreat 2018, Victor Harbor, Australia.
Kumarasamy, Chellan ; Jayaraj, Rama. / Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer. Paper presented at Adelaide Immunology Retreat 2018, Victor Harbor, Australia.
@conference{8e1719ecbfa2471293a7a496279afdf7,
title = "Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer",
abstract = "Background: A large number of immunohistochemical biomarkers that function as prognostic markers in Head and Neck Cancer (HNC) have been discovered in the past 3 decades. Despite these advancements, there is currently no designated IHC marker that sees widespread clinical use as a standard prognostic marker in HNC. Furthermore, there are very few studies that comprehensively analyse the prognostic comparative utility of these immunohistochemical markers, with the previously published studies being primarily literature reviews. Therefore, this is aimed at investigate the prognostic significance of the various immunohistochemical biomarkers identified in HNC through systematic review and meta-analysis. Methods: Clinical study data pertaining to the prognostic efficacy of IHC markers in HNC is obtained by a thorough search of bibliographic databases such as, MEDLINE, Scopus, PubMed, Web of Science, EMBASE and Science Direct, using a combination of ‘keywords’ to develop database ‘search strings’. Relevant studies are screened for and selected using strict, predefined inclusion and exclusion criteria, by two independent reviewers. HNC patient data is extracted from eligible studies using a pre-piloted data extraction form. Quantitative synthesis will be performed on patient survivaldata (with respect to the IHC markers) extracted from the selected studies as explicitly recordedstatistics or from the Kaplan-Meier (KM) Curves of the studies. A forest plot will be generated, todetermine pooled Hazard Ratios (HR) and 95{\%} Confidence Interval (CI). Discussion: There are a number of immunohistochemical biomarkers that have been discovered for estimating the prognosis of HNC patients’ clinical outcomes including. This systematic review will serve to compare and highlight IHC markers that show promising prognostic properties. Highlighting these prognostic specific IHC markers will have major clinical implications by allowing for betterestimation of disease recurrence and patient survival, by offering clinicians a method ofquantitatively analysing the value of prominent IHC markers used to assess prognosis in HNC.",
author = "Chellan Kumarasamy and Rama Jayaraj",
year = "2018",
language = "English",
note = "Adelaide Immunology Retreat 2018, AIR-14 ; Conference date: 10-08-2018 Through 11-08-2018",

}

Kumarasamy, C & Jayaraj, R 2018, 'Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer' Paper presented at Adelaide Immunology Retreat 2018, Victor Harbor, Australia, 10/08/18 - 11/08/18, .

Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer. / Kumarasamy, Chellan; Jayaraj, Rama.

2018. Paper presented at Adelaide Immunology Retreat 2018, Victor Harbor, Australia.

Research output: Contribution to conferenceConference paper presented at Conference (not in Proceedings)Research

TY - CONF

T1 - Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer

AU - Kumarasamy, Chellan

AU - Jayaraj, Rama

PY - 2018

Y1 - 2018

N2 - Background: A large number of immunohistochemical biomarkers that function as prognostic markers in Head and Neck Cancer (HNC) have been discovered in the past 3 decades. Despite these advancements, there is currently no designated IHC marker that sees widespread clinical use as a standard prognostic marker in HNC. Furthermore, there are very few studies that comprehensively analyse the prognostic comparative utility of these immunohistochemical markers, with the previously published studies being primarily literature reviews. Therefore, this is aimed at investigate the prognostic significance of the various immunohistochemical biomarkers identified in HNC through systematic review and meta-analysis. Methods: Clinical study data pertaining to the prognostic efficacy of IHC markers in HNC is obtained by a thorough search of bibliographic databases such as, MEDLINE, Scopus, PubMed, Web of Science, EMBASE and Science Direct, using a combination of ‘keywords’ to develop database ‘search strings’. Relevant studies are screened for and selected using strict, predefined inclusion and exclusion criteria, by two independent reviewers. HNC patient data is extracted from eligible studies using a pre-piloted data extraction form. Quantitative synthesis will be performed on patient survivaldata (with respect to the IHC markers) extracted from the selected studies as explicitly recordedstatistics or from the Kaplan-Meier (KM) Curves of the studies. A forest plot will be generated, todetermine pooled Hazard Ratios (HR) and 95% Confidence Interval (CI). Discussion: There are a number of immunohistochemical biomarkers that have been discovered for estimating the prognosis of HNC patients’ clinical outcomes including. This systematic review will serve to compare and highlight IHC markers that show promising prognostic properties. Highlighting these prognostic specific IHC markers will have major clinical implications by allowing for betterestimation of disease recurrence and patient survival, by offering clinicians a method ofquantitatively analysing the value of prominent IHC markers used to assess prognosis in HNC.

AB - Background: A large number of immunohistochemical biomarkers that function as prognostic markers in Head and Neck Cancer (HNC) have been discovered in the past 3 decades. Despite these advancements, there is currently no designated IHC marker that sees widespread clinical use as a standard prognostic marker in HNC. Furthermore, there are very few studies that comprehensively analyse the prognostic comparative utility of these immunohistochemical markers, with the previously published studies being primarily literature reviews. Therefore, this is aimed at investigate the prognostic significance of the various immunohistochemical biomarkers identified in HNC through systematic review and meta-analysis. Methods: Clinical study data pertaining to the prognostic efficacy of IHC markers in HNC is obtained by a thorough search of bibliographic databases such as, MEDLINE, Scopus, PubMed, Web of Science, EMBASE and Science Direct, using a combination of ‘keywords’ to develop database ‘search strings’. Relevant studies are screened for and selected using strict, predefined inclusion and exclusion criteria, by two independent reviewers. HNC patient data is extracted from eligible studies using a pre-piloted data extraction form. Quantitative synthesis will be performed on patient survivaldata (with respect to the IHC markers) extracted from the selected studies as explicitly recordedstatistics or from the Kaplan-Meier (KM) Curves of the studies. A forest plot will be generated, todetermine pooled Hazard Ratios (HR) and 95% Confidence Interval (CI). Discussion: There are a number of immunohistochemical biomarkers that have been discovered for estimating the prognosis of HNC patients’ clinical outcomes including. This systematic review will serve to compare and highlight IHC markers that show promising prognostic properties. Highlighting these prognostic specific IHC markers will have major clinical implications by allowing for betterestimation of disease recurrence and patient survival, by offering clinicians a method ofquantitatively analysing the value of prominent IHC markers used to assess prognosis in HNC.

M3 - Conference paper presented at Conference (not in Proceedings)

ER -

Kumarasamy C, Jayaraj R. Clinical Prognosis of Immunohistochemical Markers In Head And Neck Cancer. 2018. Paper presented at Adelaide Immunology Retreat 2018, Victor Harbor, Australia.